The recently released WHO guideline on hypertension treatment (2021), recommends that patients with stable blood pressure can be asked to visit clinics at 3-6 month intervals as an important strategy to improve hypertension control
Travoprost ophthalmic solution is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension
WINREVAIR is currently the first and only activin signalling inhibitor approved for PAH across all 27 EU member states
It's a development that marks a major step forward for patients struggling with moderate-to-severe chronic spontaneous urticaria
Elevidys came under scrutiny in June when the FDA disclosed two fatal cases in non-ambulatory boys who developed dangerously high liver enzyme levels
The new formulation features what Abbott calls a “triple care system,” anchored by a blend of nutrients aimed at supporting blood sugar control and metabolic health
The data highlight sustained intraocular pressure (IOP) reduction, drop-free treatment outcomes, and strong visual performance
Patients on baxdrostat showed a significant reduction in systolic blood pressure (SBP) compared to placebo
The pharma giant's 11% rise in total revenue to $43.2 billion highlights consistent execution of its growth strategy
AI-powered cardiometabolic wellness platform for India’s workforce
Subscribe To Our Newsletter & Stay Updated
